DOCSLIB.ORG

Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs and Psychotropic Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs and Psychotropic Substances UNITED NATIONS E/NL 1986/1-4 30 September 1986 ENGLISH ONLY * LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES In accordance with the relevant articles of the international treaties on narcotic drugs and psychotropic substances, the Secretary-General has the honour to communicate the following legislative texts. SWEDEN Communicated by the Government of Sweden NOTE BY THE SECRETARIAT (a) Some editing of texts may be done by the Secretariat in the interest of clarity. In this connection, words in square brackets [ ] have been added or changed by the Secretariat. (b) Only passages directly relevant to the control of narcotic drugs or psycho• tropic substances have been reproduced in this document. Non-relevant parts of laws and regulations have been deleted by the Secretariat; such deletions are indicated by [...]. INDEX PaSe E/NL.1986/1 Law Amending the Law (1960:*H8) on Penalties for the Smuggling of Goods E/NL.1986/2 Act Amending the Penal Law on Narcotics (1968:6U) 3 E/NL.1986/3 Ordinance Amending the Ordinance (1983:366) Classifying k Certain Substances as Narcotic Drugs E/NL.1986A National Board of Health and Welfare. Notification on List of Narcotics, 2 May 1985 SOSFS 1985:9 Note by the Secretariat : The present document is a direct reproduction of the texts received by the Secretariat. V.86-60352 K/NL.1986/1-4 page 2 E/NL.1986/1 SFS 1985:10 Issued by the printer's on 22 January 1985 Law amending the Law (1960:418) on Penalties for the Smuggling of Goods promulgated on 10 January 1985. Pursuant to a decision 1 by Parliament, it is prescribed that Sections 1. 2. 8. 19 and 24 in the Law on Penalties for the Smuggling of Goods (1960:418)1/ shall be worded as follows: Section l2 Any person who, without notifying the proper authority, imports or exports goods for which customs duties or other public charges should be paid to the State or which, pursuant to provisions in a law or a statute may not be imported or exported, shall, if the act is wilful, be sentenced for smuggling to a fine or to a maximum penalty of imprisonment for two years. Should the offence relate to narcotic drugs as defined in section 8 of the Penal Law on Narcotics (1968:64), 2/ the maximum penalty 6hall be imprisonment for three years. The first paragraph is also applicable when a person, by means of a misleading statement in a customs declaration or by any other deception in connection with the customs clearance of goods, wilfully avoids, payment of customs duties or other public charges to the State or imports or export goods in contravention of a prohibition. Section 23 Should the smuggling pursuant to section 1. first paragraph, be judged to be petty in the light of the value of the goods and other circumstances of the offence, the penalty shall be a fine of not more than one thousand Swedish Kronor. If the offence relates to narcotic drugs, the penalty shall be a fine or imprisonment for a maximum period of six months. Section B4 For attempted smuggling the penalty shall be as laid down in chap. 23 of the Penal Code. The same applies to preparation for or conspiracy in smuggling of narcotic drugs which is not of a petty nature. E/NL.1986/1-4 page 3 If several persons have collaborated in an act punishable under this Law. the provisions of chap. 23 of the Penal Code apply. As regards smuggling which is of a petty nature, what has now been stated only applies if the offence relates to narcotic drugs. This Law enters into force on 1 March 1985. On behalf of the Government KJELL-OLOF FELDT Leif Lindstam (Ministry of Finance) 1.Government Bill 1984/85:46. JuU 12. rskr 103 2 Most recent wording 1983:364. 3 Most recent wording 1980:1138. 4 Most recent wording 1968:65. E/NL.1986/2 SFS 1985:9 Issued by the printer's 22 January 1985 Act amending the Penal Law on Narcotics (1968:64) promulgated on 10 January 1985 Pursuant to a decision by Parliament 1. it is prescribed that Sections 1. 2 and 4 in the Penal Law on Narcotics (1968:64) shall be worded as follows: Section 1 2 Any person who unlawfully 1. transfers narcotics. 2. manufactures narcotics intended for misuse. 3. acquires narcotics for the purpose of transfer. 4. procures, processes, packages, transports, keeps or has otherwise to do with narcotics which are not intended for personal use, 5. offers narcotics for sale, keeps or conveys payment for narcotics, mediates contacts between seller and purchaser or takes any other such measure, if the procedure is designed to promote narcotics traffic, or 6. possesses narcotics E/NL. 1986/1-4 page 4 shall be sentenced, if he has acted wilfully, for a narcotics offence to imprisonment for a maximum of three years. Section 2 If it is considered that the offence referred to in Section 1 is a minor one, the perpetrator is to be sentenced to a fine or to imprisonment for a maximum of six months. Section 4 3 For an attempt to commit or preparation for a narcotics offence or a grave narcotics offence as well as for conspiracy to commit a narcotics offence, which is not considered to be a minor one,or a grave narcotics offence, the perpetrator is to be sentenced - if the offence concerns other than the possession of narcotics - for liability pursuant to Chapter 23 in the Penal Code. This Act is to enter into force on 1 March 1985. On behalf of the Government STEN WICKBOM Sten Heckscher (Ministry of Justice) ll Government Bill 1984/85:46. JuU 12. rsfcr 103 2. Most recent wording 1983:363 3. Most recent wording 1983:363 E/HL.1986/3 SFS 1985:244 Published 14th May 1985 Ordinance amending the Ordinance (1983:366) classifying certain substances as narcotic drugs. Promulgated 18th April 1985 The Government ordains that the Ordinance.-(1983:366) classifying certain substances as narcotic drugs^ ^ is to be worded as follows. The following substances are to be classified as narcotic drugs under the Drug Offences Act (1968:64): 2/ Central stimulants ethylamphetamine (2-ethylamino-l-phenyl propane) pyenetyllin [1-phenyl-l-piperidyl-(2)-methyl] acetate 1-phenyl-2-butylamine N-hydroxiamphetamine propylhexedrine E/NL. 1986/1- '» page 5 Hallucinogens 2-amino-l-(4-broraide-2,5-diniethoxiphenyl) propane (bromide-STP) hydroxi- 3-penthy1- 6,6,9 -trime thyl-6a,7,10,10a-tetrahydro- eH- 'dibensotb, d]-pyranol-(1) (hydroxitetrehydrocannabinoles) ibogain levonantradol nabilon Analgesics Carphentanil Sedatives and Tranouilisers allobarbital aprobarbital brallobarbital brotizolam butalbarbital pyrityldion (3,3-dietyl-2,4-dioxotetrahydropyridine) heptabarbital hexapropymat hexobarbital chlometiazol chloral hydrate choloralodol methohexital methylpentynol midazolam tybamat vinbarbital Furthermore, cannabis for the purposes of the law on the same, should be understood to comprise those parts above ground (except for the seeds) of every plant of the cannabis family from which the resin has not been extracted, irrespective of the names by which they may be known. This Ordinance enters into force on 1st July 1985. On behalf of the Government STEN ANDERSSON Karl-Ingvar Rundqvist (Minister of Health and Social Affairs). E/NL.1986/1- 4 page 6 E/NL.1986A National Board of Health and Welfare Notification on List of Narcotics, May 2, 1985 SOSFS 1985:9 The National Board of Health and Welfare conveys that according to the obligation given in the Narcotics Ordinance (1962:704)1/ the established list of narcotics shall read as follows: 1. Narcotics means a) substances and preparations which are Included in Schedules I, II and III, stereoisomers (with the exep- tion of dextromethorphan and dextrorphan), esters and ethers of these substances and their salts, stereoiso• mers, esters and ethers, irrespective of whether they are natural or synthetically manufactured; b) substances recorded in Schedules IV and V and the salts of these substances; c) preparations, with the exception stated below, which contain, or are extracted from substances referred to in paragraph a) above; d) preparations whether alone or compounded with others, containing substances listed in paragraph b) above; e) other preparations containing substances indicated in paragraph b) above provided that the National Board of Health and Welfare has so decided. These decisions are published by.The National Corporation of Pharmacies (Apoteksbolaget AB) in the "Price-list of Pharmaceutical Specialities", where they are indicated by the sign <$> beside the speciality's name. 2. Nacotics does not refer to the following groups of preparations intended for medical or scientific use: a) preparations of opium or morphine, containing not more than 0.2 per cent morphine, calculated as anhydrous morphine base and compounded with one or more other therapeutically active, non-narcotic ingredients; b) preparations, which, compounded with one or more other ingredients, contain any one of the following substances: ethylmorphine, pholcodine, codeine,nicodicodine, nicoco- dine, or norcodeine, to a maximum level of 100 milli• grammes in each dosage unit or to a maximum limit of 2.5 per cent in a multldose preparation; E/NL.1986/1-4 page 7 c) preparations of difenoxln containing, per dosage unit, not more than 0.5 milligramme of difenoxin, and a quantity of atropine sulphate, equivalent to at least S per cent of the dose of dife• noxin; d) preparations of diphenoxylate containing, per dosage unit, not more than 2.5 milligrammes of diphenoxylate, calculated as base, and a quantity of atropine sulphate equivalent to at least 1 per cent of the dose of diphenoxylate; e) preparations of propiram containing, per dosage unit, not more than 100 milligrammes of propiram, compounded with at least the same quantity of.methyl cellulose; f) oral preparations, containing of narcotic substances only dextro- propoxyphene to a maximum quantity of 135 milligrammes per dosage unit or to a maximum limit of 2.5 per cent in a multidose pre• paration.
Load more

Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • 02/06/2019 12:05 PM Appendix 3745-21-09 Appendix A
    ACTION: Final EXISTING DATE: 02/06/2019 12:05 PM Appendix 3745-21-09 Appendix A List of Organic Chemicals for which Paragraphs (DD) and (EE) of Rule 3745-21-09 of the Administrative Code are Applicable Organic Chemical Organic Chemical Acetal Benzaldehyde Acetaldehyde Benzamide Acetaldol Benzene Acetamide Benzenedisulfonic acid Acetanilide Benzenesulfonic acid Acetic acid Benzil Acetic Anhydride Benzilic acid Acetone Benzoic acid Acetone cyanohydrin Benzoin Acetonitrile Benzonitrile Acetophenone Benzophenone Acetyl chloride Benzotrichloride Acetylene Benzoyl chloride Acrolein Benzyl alcohol Acrylamide Benzylamine Acrylic acid Benzyl benzoate Acrylonitrile Benzyl chloride Adipic acid Benzyl dichloride Adiponitrile Biphenyl Alkyl naphthalenes Bisphenol A Allyl alcohol Bromobenzene Allyl chloride Bromonaphthalene Aminobenzoic acid Butadiene Aminoethylethanolamine 1-butene p-aminophenol n-butyl acetate Amyl acetates n-butyl acrylate Amyl alcohols n-butyl alcohol Amyl amine s-butyl alcohol Amyl chloride t-butyl alcohol Amyl mercaptans n-butylamine Amyl phenol s-butylamine Aniline t-butylamine Aniline hydrochloride p-tertbutyl benzoic acid Anisidine 1,3-butylene glycol Anisole n-butyraldehyde Anthranilic acid Butyric acid Anthraquinone Butyric anhydride Butyronitrile Caprolactam APPENDIX p(183930) pa(324943) d: (715700) ra(553210) print date: 02/06/2019 12:05 PM 3745-21-09, Appendix A 2 Carbon disulfide Cyclohexene Carbon tetrabromide Cyclohexylamine Carbon tetrachloride Cyclooctadiene Cellulose acetate Decanol Chloroacetic acid Diacetone alcohol
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Federal Controlled Substances Checklist
    Federal Controlled Substances Checklist Introduction By Norton Tooby & Joseph Justin Rollin We have reprinted here an alphabetical list of all controlled substances forbidden under federal drug laws, taken from the official website of the U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control, at http://www.justice.gov/dea/pubs/scheduling.html. No copyright is asserted to this information. This list changes frequently. The official list is contained at 21 CFR § 1308, as supplemented by final rules published in the Federal Register. The attached checklist of controlled substances has been compiled into one list, and placed in alphabetical order, for ease of reference. If a controlled substance is listed in the federal drug schedules, it triggers deportation, INA § 237(a)(2)(B)(i), 8 U.S.C. § 1227(a)(2)(B)(i), and inadmissibility. INA § 212(a)(2)(A)(i)(II), 8 U.S.C. § 1182(a)(2)(A)(i)II). In addition, there is an aggravated felony defined as illicit trafficking in a controlled substance. INA § 101(a)(43)(B), 8 U.S.C. § 1101(a)(43)(B). The same controlled substance lists apply to this ground of deportation as well. If a drug is not listed on the federal controlled substances schedules, it does not trigger removal under these grounds. In addition, because the government has the burden of proof in deportation removal proceedings by clear and convincing evidence, if the record of conviction is ambiguous as to whether the specific substance involved in the particular case was listed on the federal schedules, the government cannot obtain a deportation removal order on this ground.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Article 22 Regulation for Restriction of Synthetic Drugs
    ARTICLE 22 REGULATION FOR RESTRICTION OF SYNTHETIC DRUGS SECTION 22.1 AUTHORITY This regulation is promulgated under the authority granted to the Needham Board of Health under Massachusetts General Laws Chapter 111, Section 31 which states that “boards of health may make reasonable health regulations”. SECTION 22.2 PURPOSE The Needham Board of Health has found that synthetic marijuana, consisting of plant or other material treated with various chemicals or other synthetic substances not approved for human consumption, may be marketed and sold as herbal incense in the greater Boston area, although they are being used in the same manner and for the same purposes as scheduled drugs. In addition, the use of these products has become particularly popular among teens and young adults. Based on information and reports from hospitals, emergency room doctors, and police agencies, individuals who use these products experience dangerous side effects including convulsions, hallucinations, and dangerously elevated heart rates. This is evidence that synthetic marijuana products are harmful if inhaled or consumed, and present a significant public health danger. These synthetic compounds and others have a high potential for abuse and lack of any accepted medical use, these dangerous products, while not approved for human consumption, are marketed and sold in a form that allows for such consumption, putting at risk the individuals who come into contact with them. Therefore, the Needham Board of Health adopts this regulation for the purpose and with the intent to protect the public health and safety of the Town of Needham and its residents from the threat posed by the availability and use of synthetic marijuana, synthetic stimulants, synthetic hallucinogens, and other dangerous products by prohibiting persons from trafficking in, possessing, and using them within the town.
    [Show full text]
  • Control Substance List
    Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine
    [Show full text]